Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Ibrutinib (Imbruvica) with R-CHOP for diffuse large B-cell lymphoma – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Lymphoma is a cancer of the lymphatic system, which is part of the immune system. It contains cells called lymphocytes that fight infections. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma. It can occur at any age but is more common in those over 65 years of age.
Ibrutinib is a new drug for diffuse large B-cell lymphoma. It comes in the form of capsules that are taken by mouth and swallowed. Some studies have suggested that this drug may be helpful for people with a particular type of diffuse large B-cell lymphoma who have not yet received any chemotherapy for this disease. A study is now running and is aiming to find out how well ibrutinib works alongside chemotherapy and whether it is safe to use.
If ibrutinib is licensed for use in the UK, it could be a new treatment option for diffuse large B-cell lymphoma that may improve survival. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Humans; Lymphoma, Large B-Cell, Diffuse; Pyrazoles; Pyrimidines; Vincristine Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000435 Date abstract record published 04/03/2016 |